Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
Commentary|Videos|June 4, 2026
Oncology PulsePoints: Systemic Treatment of Thyroid Cancer: ASCO Guideline
Christine Barrett, PharmD, BCOP discusses key updates to the Systemic Treatment of Thyroid Cancer: ASCO Guideline.
Advertisement
Advertisement
Pharmacy Times interviews Christine Barrett, PharmD, BCOP to discuss key updates to the Systemic Treatment of Thyroid Cancer: ASCO Guideline and their implications for pharmacists and clinical practice.
Related to this article
Five breast cancer treatment advances in 2026 expand therapeutic options while raising questions.
Phase 3 Krascendo 1 results suggest investigational divarasib could improve survival compared with currently approved KRAS G12C inhibitors in previously treated NSCLC.
This study found that use of fixed-dose 4F-PCC is a safe, efficient alternative to weight-based dosing and can lead to cost savings for the health system.
Tucatinib’s new HER2-positive breast cancer maintenance indication extends disease control while requiring close liver monitoring and pharmacist coordination of oral therapy with ongoing antibody treatment.
The PD-1 inhibitor is the first immunotherapy approved for stage II and III MSI-H/dMMR locally advanced rectal cancer and may allow eligible patients to avoid chemotherapy, radiation, and surgery.
Public data may help identify drugs associated with shortages, but hospital inventory and purchasing data could make early-warning tools more useful.
Danielle Roman, PharmD, BCOP, FHOPA, explains how ASCO’s updated breast cancer surveillance guideline links follow-up intensity to recurrence risk and creates opportunities for pharmacist involvement.
Advertisement
Advertisement